

Recent Advances in Local Anesthesia

Tejasvinee Sahebrao Chaudhari¹, Prathmesh Gorakh Patil², Mohan Parsharam³

Habiburrehman Shaikh⁴, Saeed Ahmad⁵

Dr. Uttamrao Mahajan College of Pharmacy, Chalisgaon, India


Abstract: *Although local anesthesia remains the mainstay of pain management, research will continue to find new and effective pain management techniques. Much of the research focuses on improving anesthesia, birth and other methods. There are many new technologies that can help dentists provide better treatments, fewer harmful injections, and fewer negative side effects. Local anesthetics have a strong record of effectiveness and safety in medical and dental care. They are used so regularly and rarely that it is understandable for doctors to ignore many aspects of their medical treatment. Local anesthesia is one of the most commonly applied treatments. They include local anesthesia, topical anesthesia, infiltration anesthesia, conduction anesthesia, spinal anesthesia, epidural anesthesia and others. Classical local anesthetics are made of aminoesters and aminoamides, and their discovery and development dates back to the discovery of the first local anesthetic, cocaine. . Different local anesthetics have different clinical uses. Some important features of local anesthesia include potency, rate of onset, duration of anesthesia, depth of effect, and contrast blockade. Other factors affecting anesthesia include local anesthesia dose, addition of vasoconstrictors to local anesthesia, injection site, combination of local anesthesia, and others. Of course, side effects of local anesthetics such as neurotoxicity and cardiotoxicity should be a cause for concern. Now, two studies are particularly relevant. First, the development of new, high-yield, low-toxicity, long-acting local anesthetics should stimulate the emergence of better local anesthetics. Local anesthetics used in appropriate concentrations reversibly inhibit conduction in peripheral nerves. Local anesthetics can be used in more ways than other groups because they have an incredible track record of effectiveness and safety in desensitizing different parts of the body to pain. Since all excitable tissues are sensitive to local anesthetic blockade, these drugs can also be used as components of antiarrhythmic drugs and anesthetics. Cocaine was the first local anesthetic and was first injected into the jaw by William Halsted, a few months after Carl Koller introduced the anesthesia on September 15, 1884. Pioneers such as Halsted, James Corning, and August Bier soon developed a variety of anesthetics. The management system is still used today.*

Keywords: pain management, local anaesthesia, recent trends, Dentistry

I. INTRODUCTION

Routine dental procedures cannot be performed without the use of local anesthesia. To provide local anesthesia, dentists can use a variety of tools and techniques. Paradoxically, although local anesthesia makes dental procedures painless, it can make patients uncomfortable and frightened. Safety and effective pain management are important in today's dentistry. For most clinics, our current equipment is sufficient to administer local anesthesia to the upper jaw and lower jaw. Local anesthesia is used for dental procedures including cavity preparation, tooth preparation, scaling and root preparation, surgical procedures or endodontic treatment. In addition to examination, mouth protection and fluoride application, local anesthesia is used in almost all dental procedures, depending on the patient's pain tolerance or fear. Local anesthetics affect the nervous system by blocking the entry of sodium ions through channels or ionophores in the brain. Most of these channels are in a resting state where sodium ions cannot enter. When a neuron is stimulated, the channel assumes the state is on or off, and these sodium ions diffuse into the cell, initiating depolarization. With a sudden change in membrane voltage, sodium channels enter a passive state, while additional flow is rejected when the body processes sodium ions back to the outside. After this repolarization, the channel enters the resting state. Understanding sodium channel states helps explain the preference of local anesthetics for different types of neuronal fibers. Local anesthetics have a higher affinity for receptors on open and inactivated sodium channels than at rest.

Therefore, the fastest-firing neurons are the most sensitive to local anesthetics. In addition, small fibers are usually more affected because the volume of local anesthetic can easily block the sodium channels when necessary and thus prevent the conduction of the pulse. Disease is one of the greatest human sufferings and one of the most disturbing symptoms for patients. Acute pain is divided into two groups: acute and chronic pain, as well as pain caused by trauma, post-operative pain, osteoporosis, migraine, diabetic neuralgia, back pain, spine pain and cancer. Available analgesics generally include opioids and non-steroidal anti-inflammatory drugs. However, both drugs have some side effects. For example, opioids can cause respiratory distress, constipation, nausea and vomiting, constipation, skin irritation, biliary colic, and more. Non-steroidal anti-inflammatory drugs cause coagulation disorders, gastrointestinal ulcers, liver and kidney failure, etc. why could it be. Therefore, treatment, especially chronic pain and cancer, poses a huge challenge to healthcare. The 2015 Global Disease Survey found that the leading causes of disability are back pain and arthritis. In the United States, more than 40% of the population suffers from chronic pain. In middle- and low-income countries, the prevalence of chronic pain is 33% in adults and 56% in adults. Local anesthetics work by locally and reversibly blocking nerve impulses and have been used in medicine for more than a century. In general, the effects of local anesthetics are limited to the application site. Despite its long history of use, the effect system has not been fully implemented. There are currently three different theories that will shed light on the possible process. The first theory, known as the receptor site theory, says that under physiological conditions, local anesthetics exist in both neutral base and cationic forms. After local injection, the intermediate form of the molecule penetrates into the inner part of the nervous system from the injection site. As intracellular pH decreases, the content of the cationic form of the molecule increases. It then competes with sodium ions for sodium channel receptors by reducing the number of radio channels, reducing ion flux in the open channel, preventing the channel from transitioning to the open state, and reducing the amplitude and rate of potential rise. This can reduce pain by preventing peripheral nerves from reaching the spinal cord or brain. The second theory, called the membrane swelling theory, proposes that hydrophobic local anesthetic molecules swell cell membranes, causing changes in the membrane that constrict sodium channels and prevent action potentials. However, a limitation of this theory is that it can only explain the course of action of the average local anesthetic. The third theory is called electric charge. The theory is that the lipophilic part of the local anesthetic forms a bond with the hydrophobic cell membrane of the nerve, while the positive charge is on the other side of the molecule (e.g. protonated amine) and accumulates outside the cell membrane. In this way, even if the local anesthetic does not enter the cell, it can store enough charge to have a transmembrane potential outside the cell membrane without changing the capital. Nature is at hand. This can cause depolarization and reduce the potential to reach threshold potential, thus resulting in biological properties. However, one of the shortcomings of this theory is that it cannot explain the effects of local anesthetics such as benzocaine.



Cocaine

MECHANISM OF LOCAL ANESTHESIA

The mechanism of action may be more complicated than blockage of the inward Na^+ current, as calcium, potassium and G-protein-regulated channels may also be blocked. Lignocaine binds and dissociates rapidly from the channel, whereas bupivacaine binds rapidly but dissociates more slowly. This has little effect on neuronal block, but assumes greater importance when referring to effects on cardiac toxicity. (R)- and (S)-enantiomers of local anesthetics have been demonstrated to have a different affinity for the different ion channels of sodium, potassium and calcium, which accounts for the significant reduction of central nervous system and cardiac toxicity of the (S)-enantiomer as compared with the (R)-enantiomer. The speed of onset of block is related to the concentration of molecules of local anesthetic in the free base or non-ionized state. This depends on the initial dose and the dissociation constant (pK_a) of the local anesthetic, and the pH of the tissues. In humans the duration of anesthesia is influenced markedly by the peripheral vascular effect of the local anesthetic drug. Many local anesthetics have a biphasic effect on vascular smooth muscle: at low concentration, these agents tend to cause vasoconstriction, whereas at clinically used concentrations, they cause vasodilatation. However, differences exist in the degree of vasodilator activity produced by various drugs. In spinal cord, the pial vessels are dilated by bupivacaine, but they are constricted by ropivacaine, a finding suggesting a stereoselective effect on vascular tone independent of nerve block per se. Onset of action of LA agents differs, for example ropivacaine was faster than levobupivacaine for sciatic nerve surgical block.

GENERAL PROPERTIES OF LOCAL ANESTHETICS

The molecular structure of all local anesthetics consists of 3 components: (a) lipophilic aromatic ring, (b) intermediate ester or amide linkage, and (c) tertiary amine. Each of these components contributes distinct clinical properties to the molecule. (fig No1.)




Fig No:1

Anesthetic Potency

Local anesthetics vary in their potency, allowing for concentrations that range typically from 0.5 to 4%. This is largely the result of differences in lipid solubility, which enhances diffusion through nerve sheaths and neural membranes. This property is determined by the aromatic ring and its substitutions, along with those added to the tertiary amine. For example, bupivacaine is more lipid soluble and potent than articaine, allowing it to be formulated as a 0.5% concentration (5 mg/mL) rather than a 4% concentration (40 mg/mL).

Time for Onset

Greater lipid solubility of a drug not only enhances potency but also enables more rapid diffusion through cell membranes. For local anesthetics, this hastens the onset for anesthesia in isolated fibers during in vitro studies, but it must be appreciated that other factors come into play clinically. For example, inherent vasodilating properties may promote systemic absorption before the anesthetic reaches the nerve membrane. High lipid solubility may impede

dispersion throughout tissue fluids and also fosters sequestration in neighboring adipose tissues or myelin sheaths. In either case, fewer numbers of molecules reach the neuronal membrane and onset is delayed. Therefore, unlike in vitro studies of isolated fibers, greater lipid solubility generally slows the onset of anesthesia in the clinical setting. Injecting higher concentrations that allow a greater number of molecules to reach the membrane and hasten onset can offset this influence. Although bupivacaine and articaine are both highly lipid soluble, the 4% concentration of articaine provides for a much faster onset.

Despite myriad factors that influence the quantity of local anesthetic reaching the nerve fibers, the most important factor that determines the onset of anesthesia is the proportion of these molecules that exist in a lipid-soluble rather than a water-soluble state. The terminal amine illustrated in Figure 1 may exist in a tertiary form (3 bonds) that is lipid soluble, or as a quaternary form (4 bonds) that is positively charged and renders the molecule water soluble. For the local anesthetic base to be stable in solution, it is formulated as a hydrochloride salt. As such, the molecules exist in a quaternary, water-soluble state at the time of injection and are unable to penetrate the neuron. Therefore the time for onset of local anesthesia is directly related to the proportion of molecules that convert to the tertiary, lipid-soluble structure when exposed to physiologic pH (7.4). This proportion is determined by the ionization constant (pKa) for the anesthetic and is calculated using the Henderson-Hasselbalch equation:

$$\log \left(\frac{\text{Cationic form}}{\text{uncharged form}} \right) = \text{pKa} - \text{PH}$$

In simpler terms, if a local anesthetic were to have a pKa of 7.4 and to be injected into tissues having a physiologic pH of 7.4, 50% of the molecules would exist in the quaternary (cationic) form and 50% would exist in the tertiary (uncharged) form; only half the molecules would be lipid soluble and able to penetrate the neuron. Unfortunately, the pKa for all local anesthetics is greater than 7.4 (physiologic pH), and therefore a greater proportion of the molecules exist in the quaternary, water-soluble form when injected into normal tissue. The clinical caveat is that the higher the pKa for a local anesthetic, the fewer molecules are available in their lipid-soluble form. This will delay onset. Furthermore, the acidic environment associated with inflamed tissues lowers their pH well below 7.4 and favors the quaternary, water-soluble configuration even further. This has been suggested as one explanation for difficulty when attempting to anesthetize inflamed or infected tissues. In these situations, for example, bupivacaine (pKa 8.1) would be less desirable than mepivacaine (pKa 7.6).

It must be clarified, however, that once the tertiary molecules enter the neuron, they reionize to the quaternary form, which is credited with the actual blockade of the sodium channel. The sequence of events that leads to neural blockade is illustrated in Figure 2.




Fig No:2

Local anesthetic action. An injected local anesthetic exists in equilibrium as a quaternary salt (BH^+) and tertiary base (B). The proportion of each is determined by the pKa of the anesthetic and the pH of the tissue. The lipid-soluble base (B) is essential for penetration of both the epineurium and neuronal membrane. Once the molecule reaches the axoplasm of the neuron, the amine gains a hydrogen ion, and this ionized, quaternary form (BH^+) is responsible for the actual blockade of the sodium channel. The equilibrium between (BH^+) and (B) is determined by the pH of the tissues and the pKa of the anesthetic (pH/pKa).

Metabolism and Elimination

The intermediate chain or linkage provides a convenient basis for classification of local anesthetics, and also determines their pattern of elimination. Amides are biotransformed in the liver but esters are hydrolyzed in the bloodstream by plasma esterases. Ester local anesthetics are no longer packaged in dental cartridges and are used infrequently, with the exception of benzocaine, found in several topical anesthetic preparations. Articaine is unique in this regard. It is classified as an amide according to its intermediate linkage, but also contains an ester side chain on its aromatic ring. Hydrolysis of this side chain renders the molecule inactive, and it is therefore eliminated in a manner identical to ester anesthetics.

Duration of Action

Local anesthetics vary in their duration of action due primarily to differences in their affinity for protein. Like most drugs, local anesthetics reversibly bind to plasma proteins while circulating in the bloodstream. This property is expressed as the percentage of circulating drug that is protein bound and has been found to correlate with an anesthetic's affinity for protein within sodium channels as well. The greater the tendency for protein binding, the longer the anesthetic will sustain neural blockade. For example, bupivacaine exhibits 95% protein binding compared to 55% for mepivacaine, and this is credited for the difference in their duration of neural blockade.

Duration of anesthesia is also influenced by the time a local anesthetic remains in close proximity to neural fibers. Sequestration of highly lipid-soluble anesthetics locally may allow for continual release to the neuronal membranes, prolonging duration, but constriction of neighboring vasculature is more significant in this regard. For this reason, vasopressors are added to many formulations in order to delay absorption and prolong anesthesia. This is particularly important because local anesthetics themselves vary in their ability to produce vasodilation. For example, when used without vasopressors, lidocaine shortens its own duration by dilating local vasculature, whereas mepivacaine and bupivacaine do not. Plain lidocaine formulations may be useful for brief procedures following infiltration, but their efficacy for nerve block is poor.

LOCAL ANESTHETIC TOXICITY

Systemic toxicity attributed to local anesthetics is dose dependent, but an understanding of these doses is not always a simple matter. The use of anesthetic cartridges in dentistry has unfortunately spawned carelessness in appreciating the actual amount of anesthetic we administer to our patients. Regrettably, this practice continues to be nurtured during undergraduate training and in many well-respected dental publications. A dental cartridge represents a volume, not a dose that is more properly expressed as milligrams or micrograms. Moreover, dental cartridges often contain 2 drugs: a local anesthetic and a vasopressor, each having a separate dose. Further complicating matters, dental cartridges contain peculiar volumes such as 1.7 or 1.8 mL.

<i>Local Anesthetic (Percentage Concentration)</i>	<i>Epinephrine (Ratio Concentration)</i>
Move decimal right one space = mg/mL: 3.0% = 30 mg/mL 0.5% = 5 mg/mL	Memorize 1 : 100,000 = 10 µg/mL 1 : 50,000 = twice this (20 µg/mL) 1 : 200,000 = half this (5 µg/mL)
Example 1: 3 ½ cartridges (~7 mL): 2% lidocaine 1 : 100,000 epinephrine 7 mL × 20 mg = 140 mg lidocaine	7 mL × 10 µg = 70 µg epinephrine
Example 2: 2 ½ cartridges (~5 mL): 4% articaine 1 : 200,000 epinephrine 5 mL × 40 mg = 200 mg articaine	5 mL × 5 µg = 25 µg epinephrine

* Consider anesthetic cartridges as containing ~2 mL, not 1.7 or 1.8 mL. This error will overestimate the dosage, and is therefore a safe practice.

Table No:1

The sum of these issues makes actual dosage calculations trying and lends itself to memorization of amounts per cartridge rather than actual appreciation of proper doses. This practice becomes further complicated when cartridges contain various concentrations of local anesthetics and vasopressors. To simplify dosage calculations, it is wise to abort the concept of cartridges and consider each to contain 2 mL of volume. This will overestimate the amount administered to a patient, which is a safe practice. For example, when 4½ cartridges have been administered, estimate it as 9 mL. This unit of volume can be more easily converted to the approximate dose of each drug in milligrams or micrograms as illustrated in Table 1.

As local anesthetics are absorbed from the injection site, their concentration in the bloodstream rises and the peripheral nervous system and central nervous system (CNS) are depressed in a dose-dependent manner. (See Figure 3.) Low serum concentrations are used clinically for suppressing cardiac arrhythmias and status seizures, but ironically, higher concentrations induce seizure activity. Convulsive seizures are the initial life-threatening consequence of local anesthetic overdose. Presumably this is due to selective depression of central inhibitory tracts, which allow excitatory tracts to run amuck. As serum concentrations continue to rise further, all pathways are inhibited, resulting in coma, respiratory arrest, and eventually cardiovascular collapse. Evidence of lidocaine toxicity may commence at concentrations >5 µg/mL, but convulsive seizures generally require concentrations >10 µg/mL.




Fig No:3

It is essential that local anesthetics be respected as CNS depressants, and they potentiate any respiratory depression associated with sedatives and opioids. Furthermore, serum concentrations required to produce seizures are lower if hypercarbia (elevated carbon dioxide) is present. This is the case when respiratory depression is produced by concurrent administration of sedatives and opioids. Goodson and Moore have documented catastrophic consequences of this drug interaction in pediatric patients receiving procedural sedation, along with excessive dosages of local anesthetics.

Although all local anesthetics carry comparable risk for CNS toxicity, it should be noted that bupivacaine exhibits greater potential for direct cardiac toxicity than other agents.^{1,2} The explanation is not fully established, but is thought to be related to the fact that bupivacaine has greater affinity for the inactive and resting sodium channel configurations and

dissociates from these channels more slowly. This delays recovery from action potentials, rendering cardiac tissues susceptible to arrhythmias. This concern is relevant for certain medical procedures, during which bupivacaine is administered in very high doses. It has never been found to occur with doses up to the maximum recommended in dental anesthesia.

The obvious question is what systemic serum concentration follows administration of a particular dose of local anesthetic. In 1972, Scott et al published one in a series of landmark clinical studies assessing variables that determine subsequent concentrations of lidocaine and prilocaine in serum.⁴ It is not surprising that serum concentrations were found to vary according to the relative vascularity of the tissues in which the anesthetic was injected. Using lidocaine 400 mg, the highest serum levels illustrated in Figure 4 followed infiltration of vaginal mucosa and the lowest followed subcutaneous abdominal infiltration. In each case, however, peak serum level occurred 20–30 minutes following injection of lidocaine alone. Regardless of the route of administration, peak levels were reduced and the rate of absorption was delayed by adding epinephrine 1 : 200,000 to the local anesthetic solution. It is reasonable to assume that systemic concentrations following submucosal injection in the oral cavity would approximate those following injection into vaginal mucosa because of similar vascularity. Unfortunately, there are very few dental studies that address higher doses of local anesthetics. However, Hersh et al⁵ have published an impressive study that found comparable results following multiple intraoral injections totaling 7 cartridges (1.7 mL each = ~480 mg) of articaine containing epinephrine 1 : 200,000. (See Figure 4.) One can reasonably conclude that adhering to published maximum recommended dosages for local anesthetics will not result in systemic serum levels that approach those associated with toxicity.




Fig No:4

Additional variables were also addressed by Scott et al. As expected, the dosage and speed of injection were directly related to serum concentration. A solution's concentration, eg, 2 versus 4%, was not relevant; serum concentrations were related to the total dosage. Administering 20 mL of 2% or 10 mL of 4% (400 mg) produced the same serum concentration. When using lidocaine or other anesthetics, regardless of their formulated concentration, one must consider the dosage (milligrams) administered, not the volume (milliliters or cartridges).

Contrary to conventional thought, the age or weight of a patient does not predict systemic serum concentration following doses calculated as milligrams per age (years) or milligrams per kilogram. However, when managing pediatric patients, maximum dosages are conventionally expressed in mg/kg, and this should be followed as a precaution. It is of little relevance for adults, however, and one should adhere to guidelines expressed as maximum dose

in milligrams, regardless of weight or age. Obviously, this maximum amount should not be exceeded when calculating mg/kg doses for large children.

When considering the toxicity of any drug class, one should be mindful of metabolites, as well as the parent drug. A metabolite of prilocaine, *o*-toluidine, can oxidize the iron in hemoglobin from ferrous (Fe^{2+}) to ferric (Fe^{3+}). Hemes so altered do not bind oxygen and normal hemes on the same hemoglobin molecule do not readily release their oxygen. This form of hemoglobin is called methemoglobin, and when >1% of total hemoglobin is so altered, the condition is called methemoglobinemia. Patients appear cyanotic and become symptomatic when the proportion of methemoglobin exceeds 15%.⁶ Hemoglobin saturation by pulse oximetry (SpO_2) will decline despite clinical evidence of effective oxygenation and ventilation. For example, pulse oximeter readings may be <90%, but actual arterial oxygen tension (PaO_2) may be within normal range (>80 mm Hg). The condition becomes life threatening when methemoglobin levels exceed 50–60%, and it is managed using intravenous methylene blue, which reduces the hemes to their normal state. Methemoglobinemia attributed to prilocaine is unlikely to follow the administration of recommended doses. Rarely, one may encounter a patient with hereditary methemoglobinemia, which contraindicates the use of prilocaine.

Recent advances in local anesthetic drugs

Articaine and centbuclidine are two relatively recent medications that have been shown to be as effective as or perhaps more effective than lignocaine.

Mechanism of Action of Articaine

Articaine is a local anesthetic that is a member of the amide family. It has an ester group that is processed by tissues' esterases and a thiophene ring in place of a benzene ring. Articaine has an exponential half-life and is eliminated over an extended period of time. Unidentified plasma esterases are mostly responsible for metabolism in the liver and plasma.

Articaine Versus Lignocaine

Articaine has a faster onset of action and longer duration of action. Its success rate is greater. Articaine has more strong effects (1.5 times more potent) and has a lower level of systemic intoxication.

Adverse Effects of Articaine

Similar to prilocaine, articaine has the potential to produce neuropathies and methemoglobinemia. Articaine and prilocaine have increased paresthesia incidence, mainly with the lingual nerve, indicating that they have a more neurotoxic effect than lidocaine. It has been observed that taking articaine, particularly for infraorbital nerve block, can cause eye problems. The enhanced drug diffusion across tissues, including bone, may be the cause of this.

Centbuclidine

Centbuclidine is a local anesthetic molecule that was created in 1983 at Lucknow, India's Centre for Drug Research. It functions as a local anesthetic and is a quinolone derivative. It naturally contains antihistaminic and vasoconstricting effects. Centbuclidine, which has an anesthetic power 4-5 times larger than that of 2% lignocaine, can be used successfully for infiltration, nerve blocks, and spinal anesthesia at a concentration of 0.5% .

Although clinicians have strangely failed to capitalize on its advantages and also validate its use in the management of pain during dental procedures, this unique chemical has been extensively used in ophthalmology and other medical disciplines. Centbuclidine, according to Gune and Katre , is comparable to lignocaine and can be used as a substitute in cases of hypersensitivity in patients aged 12-14, as well as in cases of cardiac and thyroid diseases where these vasoconstrictors are prohibited.

Alternative dental anesthesia

These techniques do not substitute conventional dental anesthesia. These techniques are used as an adjunct to conventional anesthesia to reduce pain during the administration of local anesthetics.

Electric Dental Anesthesia

It is a frequently employed non-pharmacological approach for treating both acute and ongoing pain. Transcutaneous electrical nerve stimulation (TENS) uses an electrical current generated by a machine to stimulate nerves, mostly for remedial purposes. Because the equipment does not include any syringes, it instills positive behavior in kids and lessens their apprehension. Hence, pediatric patients can benefit from this method. It can also be equally helpful for adult patients to produce analgesia during various conditions such as placing rubber dams, preparing cavities, capping pulp,

performing endodontic procedures, preparing prosthetic teeth, performing oral prophylaxis, and extractions, and also to lessen pain during local anesthetic injection.

Laser Analgesia

Low-level laser therapy (LLLT) is used in a non-thermogenic, noninvasive procedure to biomodulate the tooth pulp. Similar to infiltrative local anesthesia, LLLT does not induce profound anesthesia or a total loss of sensation. The sodium-potassium (Na-K) pump is temporarily disrupted by the principle's modification of neuronal cell activity, which prevents impulse transmission and produces the analgesic effect. Children and teens experience less anxiety as a result of accepting laser dental treatment. The effectiveness of the neodymium-doped yttrium aluminum garnet (Nd:YAG) laser in inducing pulpal analgesia was confirmed by Chan et al. to be comparable to that of 5% eutectic mixture of lidocaine 2.5% and prilocaine 2.5% (EMLA) anesthetic cream. Chan et al. also proposed that laser therapy may be a novel, noninvasive treatment option for children who are needle-phobic.

Virtual Anesthesia

The most often used behavioral strategies for reducing dental anxiety are distraction tactics. Virtual reality (VR) equipment is currently a more entertaining type of diversion. Despite these drawbacks, numerous researchers have claimed that it lessens discomfort and enhances patient satisfaction during treatment. A decrease in pain and anxiety during pediatric dental treatments was reported in clinical investigations on VR. These findings suggest that VR can be utilized as a complementary technique for non-pharmacological analgesia. This is known as "virtual anesthesia" because of the analgesic potential of VR. According to Atzori et al. and Nunna et al., VR is an effective method for assisting kids in dealing with dental fillings and extractions in a way that is less stressful and more enjoyable than its alternative.

Cryoanesthesia

This procedure involves cooling a constricted body area with ice or refrigerant sprays to prevent nerves from transmitting pain signals. Hence, the topical administration of cold would stimulate pain-inhibitory pain pathways and excite myelinated A-fibers. By reducing the threshold of tissue nociceptors and pain-carrying conduction nerve signals, cooling leads to neuropraxia. According to Hindocha et al., 5% lidocaine gel during needle insertion has the same effect as applying ice to the oral mucosa as a topical anesthetic prior to injection. After application, the topical anesthetic's effects persist for a few minutes. Bose et al. claimed that precooling the soft tissue area before routine dental operations decreases the pain perception for infiltrations and blocks anesthesia in youngsters. It is a simple, dependable, and economical technique. According to a comprehensive review by Tirupathi and Rajasekhar, precooling with ice before administering local anesthetic lowers pain more effectively than refrigerant spray.

Local Toxicity

Ischemic necrosis of tissues may follow injections of local anesthetics. This can be due to the irritating nature of a solution, pressure from large volumes, or constriction of the vasculature by vasopressors. This concern is greatest when injecting into attached mucosa such as the hard palate. There is also mounting concern regarding direct neurotoxicity related to formulations containing high concentrations such as 4% articaine and prilocaine.

Haas and Lennon reported an increased incidence of paresthesias in Canada following the introduction of articaine in the mid-1980s. In 1993 alone, 14 cases of paresthesia were reported, and all were attributed to articaine or prilocaine. When articaine was first submitted for approval to the Food and Drug Administration in the United States, it was identified as having a higher risk for paresthesia than lidocaine.

More recently, Garisto et al.¹⁵ reviewed claims of paresthesia in the United States during the period of November 1997 through August 2008 and found 248 cases of paresthesia following dental procedures. Most cases (~95%) involved mandibular nerve blocks, and in 89% of these the lingual nerve was affected. Compared to other local anesthetics, paresthesia was found to be 7.3 times more likely with 4% articaine and 3.6 times more likely with 4% prilocaine. Similar findings from reports of paresthesia in Denmark were published by Hillerup et al.¹⁶ This data may be even more significant when one considers the number of cases that may very well go unreported.

Although the dental community has been slow to reach consensus regarding this issue, it should be appreciated that the medical anesthesia literature is emphatic in claiming that greater concentration of local anesthetic solutions increases risk for direct neurotoxicity to nerve trunks: "All the clinically used local anesthetics can produce direct toxicity to nerves if they achieve sufficiently high intraneural concentrations. Clinicians should be aware that the concentrations of

formulated local anesthetic solutions are neurotoxic per se and that their dilution, in situ or in tissue, is essential for safe use.”¹

This fact is further supported by Hillerup et al, who demonstrated greater neural toxicity of 4 compared to 2% articaine in sciatic nerve preparations.¹⁷ As with all drugs, each practitioner needs to perform a risk-benefit analysis before using a medication. Only if the benefit of using articaine outweighs the risk for this practitioner in this patient should it be considered for use. It might be wise to limit the use of 4% concentrations for infiltration and avoid their use for nerve blocks, opting instead for agents formulated in lower concentrations.

Maximum Doses for Local Anesthetics

Based on the data originally presented by Scott et al, lidocaine 400 mg injected submucosally produces systemic serum concentrations well below toxic levels. This is approximately the amount found in 10 dental anesthetic cartridges, and this number has been cited historically as the limit per dental appointment. Notwithstanding the fact that somewhat higher amounts can be used when formulated with vasopressors, this suggestion is obviously a safe guideline for lidocaine.

The elimination half-life ($T_{1/2\beta}$) of the various local anesthetics ranges from 90 minutes for conventional agents such as lidocaine to >200 minutes for agents such as bupivacaine. This decline commences after peak serum concentration is achieved: approximately 20 minutes with anesthetics alone⁴ and ~20–30 minutes for those combined with vasopressors. Once the peak concentration is achieved, additional doses will become absorbed as original doses are in decline. This is a perilous time because one cannot accurately predict the serum concentration at any period. Furthermore, patient responses follow a bell-shaped pattern of distribution and render these theoretical calculations even more problematic. Keep in mind that both liver and renal functions decline 50% by age 65 and beta blockers reduce hepatic blood flow. Articaine is the exception because it has an ester side chain and is inactivated in serum by plasma choline esterases.

Frequently the dentist administers a combination of local anesthetic formulations, and it must be appreciated that systemic effects of these combinations follow principles of summation. When adhering to maximum dosage guidelines, systemic effects of various agents should be regarded as additive. For example, if you have administered half the maximum dose for lidocaine and wish to add bupivacaine, reduce its maximum dose by half.

Vasopressors

Vasopressors are drugs that narrow blood vessels by activating alpha-1 adrenergic receptors. They are used together with local anesthetics to provide hemostasis in the surgical area and delay the absorption of the anesthetic agent. Delaying local anesthetic absorption not only reduces the risk of toxicity but also prolongs the duration of anesthesia. Epinephrine is the drug most commonly used for this purpose, but it has been found to be useful for cardiac stimulation due to its additive effect as a beta-1 adrenergic agonist. Despite the popularity of epinephrine 1:100,000, greater than 1:200,000 (5 $\hat{\text{A}}\mu\text{g}/\text{mL}$) has a slight advantage. Higher concentrations do not provide better onset or duration of negative alveolar blockade. Higher concentration also does not reduce the blood concentration of the local anesthetic. However, more such as 1: 100,000 (10 $\hat{\text{A}}\mu\text{g}/\text{mL}$) and 1:50,000 (20 $\hat{\text{A}}\mu\text{g}/\text{mL}$) may provide better hemostasis when entering the surgical site. This is where intervention is needed.

Drug Interactions

Potential drug interactions are discussed in detail in the appendix earlier in this book. The most important of these is related to cardiovascular development. Vasopressor drugs found in local anesthetics have cardiotoxic effects, and this may be even more important when the patient is taking drugs with similar effects. These medications include tricyclic and monoamine oxidase inhibitor antidepressants, digoxin, thyroid hormones, or a sympathomimetic drug used for weight control or depression. The use of vasopressors is not contraindicated in these patients, but should be used with caution in patients with serious disease, as described above. It is important to avoid vasopressors completely in patients suspected of using stimulant drugs such as cocaine. It is recommended to be careful in the use of vasopressors in patients who do not prefer beta blockers. Unlike selective drugs, which only block beta1 receptors in the heart, nonselective drugs also block beta2 receptors in the blood vessels. In this case, the alpha-agonist effect of the vasopressor becomes more pronounced and diastolic and mean arterial pressures become dangerous. This is often accompanied by a sudden reflex slowing of the heart rate. The main effect of this intersection is well documented. Interaction with beta-blockers occurs concurrently with the cardiovascular response to epinephrine. It begins after

absorption at the injection site, usually increases within 5 minutes and decreases over the next 10-15 minutes. The use of vasopressors is not contraindicated in patients using non-selective beta blockers, but the dose should be conservative and blood pressure should be monitored periodically during the control period as described above. The use of gingival retraction cords impregnated with racemic epinephrine should be avoided. This product contains much more epinephrine than is found in local anesthetics.

II. CONCLUSION

Local analgesia is a safe and reliable pain management technique. One of the basic principles of dentistry today is its application. Local anesthesia technique is not similar to today's technique. Today's methods are widely touted for their benefits and have many uses in dentistry. Modern techniques for effective and painless application of local anesthesia make the procedure more enjoyable for the dentist and the patient, which has a positive effect on establishing the patient-physician relationship. Since the discovery and development of cocaine as a local anesthetic, many derivatives have been developed by pharmaceutical companies and university researchers. The emergence of procaine and lidocaine marked a new era in the development of local anesthesia. The later discovery of local anesthetics such as bupivacaine and ropivacaine made the use of local anesthetics more effective. However, classical local anesthesia still has some shortcomings. In recent years, new chemical compounds (NCEs) of local anesthetics have not been found. Due to the urgent need for long-term local anesthesia, new generation new local anesthetics will achieve long-lasting results. Much of the success in the development of long-lasting local anesthesia comes from drug carriers, existing local anesthetic products, the TRP channel-based sodium blocker QX-314, etc. may be caused by class I sodium channel blockers or existing local anesthetics. combined with hormones, opiate agonists/blockers and HCN receptor agonists. Among them, bupivacaine liposomes and saxitoxinanalogs are undergoing clinical trials and are expected to be used in wide clinical applications.

REFERENCES

- [1]. Handbook of local anesthesia, 5th edition. Rosenberg M. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526219/> *AnesthProg*. 2005;52:39–40. [Google Scholar]
- [2]. An alternative local anaesthesia technique to reduce pain in paediatric patients during needle insertion. Lee SH, Lee NY. <https://pubmed.ncbi.nlm.nih.gov/23758459/> *Eur J Paediatr Dent*. 2013;14:109–112. [PubMed] [Google Scholar]
- [3]. Clinical evaluation and comparison of 2 topical anesthetics for pain caused by needle sticks and scaling and root planing. Carr MP, Horton JE. *J Periodontol*. 2001;72:479–484. [PubMed] [Google Scholar]
- [4]. Pain and anxiety reduction using a manual stimulation distraction device when administering local analgesia oro-dental injections: a multi-center clinical investigation. Touyz LZ, Lamontagne P, Smith BE. <https://pubmed.ncbi.nlm.nih.gov/15688965/> *J Clin Dent*. 2004;15:88–92. [PubMed] [Google Scholar]
- [5]. The effect of warming local anesthetic solutions prior to injection. Rogers KB, Fielding AF, Markiewicz SW. <https://pubmed.ncbi.nlm.nih.gov/2639844/> *Gen Dent*. 1989;37:496–499. [PubMed] [Google Scholar]
- [6]. Preliminary study of patient reaction to needle gauge. Hamburg HL. <https://pubmed.ncbi.nlm.nih.gov/4505144/> *N Y State Dent J*. 1972;38:425–426. [PubMed] [Google Scholar]
- [7]. Alternative local anaesthetic delivery systems, devices and aids designed to minimise painful injections - a review. Chong BS, Miller JE, Sidhu SK. <http://qmro.qmul.ac.uk/xmlui/handle/123456789/19214> *ENDO*. 2014;8:7–22. [Google Scholar]
- [8]. Newer local anesthetic drugs in dentistry. Poojashree B, Santhosh Kumar MP. https://www.researchgate.net/publication/325555353_Newer_local_anesthetic_drugs_in_dentistry *Drug Invent Today*. 2018;10:496–502. [Google Scholar]
- [9]. Comparison of 0.5% centbucridine and 2% lignocaine as local anesthetic agents for dental procedures in children: a randomised controlled trial. Gune NS, Katre AN. *Indian J Pediatr*. 2020;87:268–274. [PubMed] [Google Scholar]

- [10]. Delivery systems of local anesthetics in dentistry: an update. Thilak N. <https://actascientific.com/ASDS/pdf/ASDS-04-0829.pdf> *ActaSci Dent Sci.* 2020;4:23–27. [Google Scholar]
- [11]. Laser analgesia with pulsed infrared lasers: theory and practice. Walsh LJ. https://www.researchgate.net/publication/43496636_Laser_Analgesia_with_Pulsed_Infrared_Lasers_Theory_and_Practice *J Oral Laser Appl.* 2008;8:7–16. [Google Scholar]
- [12]. Laser in paediatric dentistry: patient acceptance of hard and soft tissue therapy. Genovese MD, Olivi G. <https://pubmed.ncbi.nlm.nih.gov/18380525/> *Eur J Paediatr Dent.* 2008;9:13–17. [PubMed] [Google Scholar]
- [13]. Pulsed Nd: YAG laser induces pulpal analgesia: a randomized clinical trial. Chan A, Armati P, Moorthy AP. *J Dent Res.* 2012;91:79–84. [PubMed] [Google Scholar]
- [14]. Effectiveness of two topical anaesthetic agents used along with audio visual aids in paediatric dental patients. Agarwal N, Dhawan J, Kumar D, Anand A, Tangri K. *J ClinDiagn Res.* 2017;11:0–3. [PMC free article] [PubMed] [Google Scholar]
- [15]. Effect of audiovisual distraction with 3D video glasses on dental anxiety of children experiencing administration of local analgesia: a randomised clinical trial. Nuvvula S, Alahari S, Kamatham R, Challa RR. *Eur Arch Paediatr Dent.* 2015;16:43–50. [PubMed] [Google Scholar]
- [16]. Virtual reality analgesia for pediatric dental patients. Atzori B, Lauro Grotto R, Giugni A, Calabrò M, Alhalabi W, Hoffman HG. *Front Psychol.* 2018;9:2265. [PMC free article] [PubMed] [Google Scholar]
- [17]. Comparative evaluation of virtual reality distraction and counter-stimulation on dental anxiety and pain perception in children. Nunna M, Dasaraju RK, Kamatham R, Mallineni SK, Nuvvula S. *J Dent Anesth Pain Med.* 2019;19:277–288. [PMC free article] [PubMed] [Google Scholar]
- [18]. Berde CB, Strichartz GR. Local anesthetics. In: Miller RD, Eriksson LI, Fleisher LA, et al., editors. *Miller's Anesthesia. 7th ed.* Philadelphia, Pa: Elsevier, Churchill Livingstone; 2009. [Google Scholar]
- [19]. Katzung BG, White PF. Local anesthetics. In: Katzung BG, Masters SB, Trevor AJ, editors. *Basic and Clinical Pharmacology. 11th ed.* New York, NY: McGraw-Hill Companies Inc; 2009. [Google Scholar]
- [20]. Goodson JM, Moore PA. Life-threatening reactions after pedodontic sedation: an assessment of narcotic, local anesthetic and antiemetic drug interactions. *J Am Dent Assoc.* 1983;107:239–245. [PubMed] [Google Scholar]
- [21]. Scott DB, Jebson PJR, Braid DP, et al. Factors affecting plasma levels of lignocaine and prilocaine. *Brit J Anaesth.* 1972;44:1040–1049. [PubMed] [Google Scholar]
- [22]. Hersh EV, Giannakopoulos H, Levin LM, et al. The pharmacokinetics and cardiovascular effects of high-dose articaine with 1 : 100,000 and 1 : 200,000 epinephrine. *J Am Dent Assoc.* 2006;137:1562–1571. [PubMed] [Google Scholar]
- [23]. Benz EJ. Disorders of hemoglobin. In: Longo DL, Kasper DL, Jameson JL, et al., editors. *Harrison's Principles of Internal Medicine. 18th ed.* New York, NY: McGraw Hill; 2012. [Google Scholar]
- [24]. Schatz M. Adverse reactions to local anesthetics. *Immunol Allergy Clin North Am.* 1992;12:585–609. [Google Scholar]
- [25]. Gell PGH, Coombs RRA. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Hachmann PJ, editors. *Clinical Aspects of Immunology. 3rd ed.* Oxford, England: Blackwell Scientific; 1975. [Google Scholar]
- [26]. Adkinson NF, Jr. Drug allergy. In: Adkinson NF Jr, Yunginger JW, Busse WW, et al., editors. *Middleton's Allergy: Principles and Practice. 6th ed.* Philadelphia, Pa: Mosby Inc; 2003. [Google Scholar]
- [27]. Gall H, Kaufmann R, Kalveram CM. Adverse reactions to local anesthetics: analysis of 197 cases. *J Allergy ClinImmunol.* 1996;97:933–937. [PubMed] [Google Scholar]
- [28]. Orr PM, Shank BC and Black AC. The role of pain classification systems in pain management. *Crit Care NursClin North Am* 2017; 29: 407-418.
- [29]. Stein C. [Pain inhibition by opioids-new concepts]. *Schmerz* 2019; 33: 295-302.
- [30]. Enthoven WT, Roelofs PD, Deyo RA, van Tulder MW and Koes BW. Non-steroidal anti-inflammatory drugs for chronic low back pain. *Cochrane Database Syst Rev* 2016; 2: Cd012087.

- [31]. Sunara P, Kronic D and Puljak L. Adverse drug reactions of non-opioid and opioid analgesics reported to croatian national authority from 2007 to 2014. *Acta Med Acad* 2017; 46: 94- 104.
- [32]. Huerta C, Castellsague J, Varas-Lorenzo C and Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. *Am J Kidney Dis* 2005; 45: 531- 539.
- [33]. Liljestrand G: The historical development of local anesthesia. In: Lechat P, ed: *International Encyclopedia of Pharmacology and Therapeutics*, Sect. 8, Local Anesthetics, vol. 1. New York, Pergamon Press, Ltd., 1971.
- [34]. Fink BR: Leaves and needles: the introduction of surgical local anesthesia. *Anesthesiology* 1985;63:77-83.
- [35]. Aberg G. Toxicological and local anesthetic effects of optically active isomers of two local anesthetic compounds. *ActaPharmacolToxicolScand* 1972;31:273-86
- [36]. Iida H, Watanabe Y, Dohi S, Ishiyama T. Direct effects of ropivacaine and bupivacaine on spinal pial vessels in canine. *Anesthesiology* 1997;87:75-81
- [37]. Casati A, Borghi B, Fanelli G, et al. A double-blinded, randomized comparison of either 0.5% levobupivacaine or 0.5% ropivacaine for sciatic nerve block. *AnesthAnalg* 2002;94:987-90